
Four Things to Learn While the Medication Is Still Working
Two thirds of the weight lost on semaglutide came back within a year of stopping it. That is not drug failure. It is a missing layer of care, and here is what belongs in it.
Read article →The Dr. Z Journal
Evidence-based obesity medicine from a board-certified endocrinologist. How GLP-1 therapies work, what belongs around the prescription, and how to protect muscle while losing fat.
Semaglutide targets one gut-hormone receptor. Tirzepatide targets two. Which matters more depends entirely on who is asking.
Read the story →
Explore the journal
Clear answers for complex health questions, written with care.

Two thirds of the weight lost on semaglutide came back within a year of stopping it. That is not drug failure. It is a missing layer of care, and here is what belongs in it.
Read article →
Oral semaglutide 25 mg was approved for chronic weight management. An endocrinologist explains the trial results, the dosing rules, and who it suits.
Read article →
A meaningful share of weight lost on GLP-1 medications is lean tissue. Here is why it happens, why it matters metabolically, and how to prevent most of it.
Read article →
The WHO now recommends GLP-1 therapy alongside intensive behavioral support. An endocrinologist explains what belongs around the medication and why.
Read article →